Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting

Published: 2025-06-03 12:05:42 ET LEGN

Published on 06/03/2025 at 12:05

Legend Biotech Corporation announced new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RMM patients were treated with a single infusion of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. In patients with EMD (CARVYKTI, n=21; standard therapies, n=18): Median PFS was 13 months with CARVYKTI®?

versus 4 months with standard therapies (HR, 0.71 [95% CI, 0.34-1.49); Median OS was not reached (NR) with 16 months with standard therapies (HR), By 1, 2, or 3 prior lines of therapy (pLOT) (CARVYKTI®?, n=68, 83, 57; standard therapies, n=68, 87, 56): In patients with one pLOT: Median PFS was NR with CARVYKTI?? versus 17 months with standard therapies (HR, 0.41 [95% CI,0.25-0.67); Median OS was NR with CARVY KTI®? versus NR with standard therapies (HR,0.56 [95% CI, 0.,28-1.11); In patients with two pLOT: Median P FS was NR with CARVYkTI®?

versus 12 months with standard therapies (HR., 0.30 [95% CI, 0.'19-0.49); Median OS was NR withCARVYKTI®®? versus NR with standard therapy (HR, 0.63 [95% CI, 0".36-1.09); In patients with three pLOT: Median PSS was NR with CARVYGTI®? versus 8 months with standard therapies (HR.20 [95% CI, 0;11-0.34); median OS was NR with CARVyKTI®?

versus 34 months with standard therapies (HR the company, 0.49 [95% CI, 0 the26-0.91); These data further support a favorable benefit-risk profile for CARVYKTI®®®? as early as after first relapse for multiple myeloma patients who are lenalidomide-refractory and have a poor prognosis. LB1908: Preliminary results of a Phase 1 study of a CLDN18.2-targeted CAR T-cell therapy show manageable safety and antitumor activity in patients with gastroesophageal cancers (Abstract #4022).

Interim data from a Phase 1, first-in-human, open-label, multicenter study of LB1908, an autologous CAR-T targeting Claudin 18.2, were presented in patients with advanced gastric, gastroesophageal, and esophageal, and esphageal adocarcinoma (GC/GEJC/EC) who are relapsed or refractory to one or more prior line of therapy and whose tumors express CLDN18.2 in 50% or more tumor cells. LB1908 demonstrated peripheral expansion and early signs of antitumor activity at the lowest dose tested, with a manageable safety profile. LB2102: Preliminary results of the study of the study of the clinical study of LB1908: Prel preliminary results of a CLDN18.

2-targeted CAR T- cell therapy show manageable safety and antitUMor activity in patients with gastroESophageal cancers (Abstract No4022).